OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 22.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 179,266 shares of the company's stock after buying an additional 32,329 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC's holdings in Roivant Sciences were worth $2,121,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of the company. Russell Investments Group Ltd. increased its stake in shares of Roivant Sciences by 478.6% in the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock worth $28,000 after purchasing an additional 1,948 shares in the last quarter. Aster Capital Management DIFC Ltd bought a new stake in Roivant Sciences during the 4th quarter valued at $39,000. GAMMA Investing LLC lifted its position in shares of Roivant Sciences by 57.0% during the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock worth $42,000 after acquiring an additional 1,288 shares in the last quarter. PNC Financial Services Group Inc. grew its position in shares of Roivant Sciences by 27.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock valued at $84,000 after purchasing an additional 1,507 shares in the last quarter. Finally, Wells Fargo & Company MN raised its stake in shares of Roivant Sciences by 84.1% during the 4th quarter. Wells Fargo & Company MN now owns 7,501 shares of the company's stock valued at $89,000 after purchasing an additional 3,426 shares during the period. 64.76% of the stock is owned by hedge funds and other institutional investors.

Roivant Sciences Stock Performance

Roivant Sciences stock traded up $0.03 during midday trading on Friday, hitting $10.79. 3,709,915 shares of the company's stock were exchanged, compared to its average volume of 5,585,504. The stock has a 50-day moving average price of $10.51 and a two-hundred day moving average price of $11.08. Roivant Sciences Ltd. has a 52-week low of $8.73 and a 52-week high of $13.06. The company has a market cap of $7.70 billion, a P/E ratio of -71.93 and a beta of 1.23.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last issued its quarterly earnings data on Monday, February 10th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. As a group, sell-side analysts expect that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

Insider Buying and Selling at Roivant Sciences

In related news, COO Eric Venker sold 100,000 shares of the firm's stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $10.65, for a total transaction of $1,065,000.00. Following the transaction, the chief operating officer now directly owns 896,869 shares of the company's stock, valued at approximately $9,551,654.85. This trade represents a 10.03% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Vivek Ramaswamy sold 273,959 shares of the company's stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $11.47, for a total value of $3,142,309.73. Following the completion of the sale, the insider now directly owns 39,799,611 shares of the company's stock, valued at approximately $456,501,538.17. This represents a 0.68% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,223,959 shares of company stock worth $13,420,035 over the last three months. 7.90% of the stock is owned by insiders.

Analyst Ratings Changes

Several brokerages have commented on ROIV. Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a research note on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and set a $18.00 price objective on shares of Roivant Sciences in a research note on Monday, April 21st.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.